Schonfeld Strategic Advisors LLC Makes New Investment in Indivior PLC (NASDAQ:INDV)

Schonfeld Strategic Advisors LLC bought a new position in shares of Indivior PLC (NASDAQ:INDV - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 135,661 shares of the company's stock, valued at approximately $1,686,000. Schonfeld Strategic Advisors LLC owned about 0.10% of Indivior at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Claret Asset Management Corp bought a new stake in Indivior in the fourth quarter valued at approximately $9,304,000. CenterBook Partners LP raised its holdings in Indivior by 105.5% during the 4th quarter. CenterBook Partners LP now owns 1,147,841 shares of the company's stock worth $14,268,000 after purchasing an additional 589,158 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Indivior by 659.7% in the 4th quarter. Marshall Wace LLP now owns 506,782 shares of the company's stock valued at $6,299,000 after purchasing an additional 440,072 shares during the last quarter. SIH Partners LLLP acquired a new stake in shares of Indivior during the fourth quarter worth $2,698,000. Finally, Boothbay Fund Management LLC boosted its position in Indivior by 65.5% during the fourth quarter. Boothbay Fund Management LLC now owns 458,874 shares of the company's stock valued at $5,879,000 after acquiring an additional 181,637 shares during the last quarter. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior Trading Up 0.5%

Indivior stock traded up $0.06 during midday trading on Monday, reaching $11.14. The stock had a trading volume of 135,203 shares, compared to its average volume of 996,272. The company has a fifty day moving average price of $9.97 and a two-hundred day moving average price of $10.57. Indivior PLC has a 12 month low of $7.33 and a 12 month high of $18.59. The company has a market capitalization of $1.54 billion, a P/E ratio of -31.76 and a beta of 0.98.

Indivior (NASDAQ:INDV - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.19. The firm had revenue of $266.00 million for the quarter, compared to the consensus estimate of $240.13 million. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. On average, equities research analysts predict that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

INDV has been the subject of several research analyst reports. RODMAN&RENSHAW raised Indivior to a "strong-buy" rating in a research report on Tuesday, January 28th. Rodman & Renshaw started coverage on Indivior in a research note on Tuesday, January 28th. They issued a "buy" rating and a $16.00 price target on the stock. Finally, Piper Sandler cut their price target on Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a report on Thursday, March 6th.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.